MONTREAL, June 12 /CNW Telbec/ - Akela Pharma Inc. (TSX: "AKL"), a drug
development company focused on developing therapies for the inhalation and
pain markets, today announced that it has been awarded a development contract
from Pear Tree Pharmaceuticals, Inc. at its PharmaForm subsidiary located in
Austin, Texas, for the development of two different drug products for
treatment of atrophic vaginitis. PharmaForm will develop the drug products to
deliver Pear Tree's confidential drug substances to the vaginal cavity.
